The US Food and Drug Administration should exercise “great caution” in allowing a COVID-19 vaccine to be deployed through an emergency use authorization rather than through the preferred route of a biologics license application approval, the National Vaccine Advisory Committee said.
The preference for a BLA over an EUA is one of five recommendations NVAC mades in a letter to Brett...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?